Joining together to expand the power of the genome
As a global leader in genomics, we continually strive to offer solutions that are not only innovative, but also accessible and always reliable. Illumina partnerships help advance genomics in numerous ways, from expanding access to next-generation sequencing (NGS) to pioneering new applications and technologies, providing funding for innovative startups, and more.
Illumina and Roche partner to broaden the adoption of distributable next-generation sequencing-based testing in oncology.
Illumina forms multiple partnerships to develop precision oncology solutions.
Illumina expands collaboration with Janssen to advance molecular residual disease cancer test.
Discover more Illumina partnerships and collaborations designed to advance access to groundbreaking genomics solutions.
The partnership will expand capabilities for countries most impacted by tuberculosis to more effectively detect and combat multidrug-resistant TB.
The partnership focuses on commercializing oncology in vitro diagnostic (IVD) kits to support patient management and may expand to other clinical fields in the future.
The partnership brings together revolutionary Illumina NGS tools and a high-quality proprietary gut microbiome analysis platform from Microba to rapidly process large volumes of metagenomic data.
The partnership supports genomic analysis customers with innovative, secure cloud-based data processing, management, and storage.
We strive to offer the best possible technologies and solutions to our customers. By integrating our technology with other best-in-class solutions, we aim to improve workflows, support groundbreaking research, and continue advancing genomics.
With mentorship, financial support, and access to sequencers and reagents, the Illumina for Startups program is helping genomics startups launch so we can unlock the power of the genome—together.
Researchers at Okayama University in Japan use Illumina Connected Analytics with DRAGEN pipelines for analyzing whole-genome, exome, transcriptome, and metagenome data
Illumina collaborated on a study presented at ASCO 2025 showing that circulating tumor DNA provides actionable data for clinical trials